ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0714

Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry

Daniel J Lovell1, Nikolay Tzaribachev2, Esi Morgan3, Gabriele Simonini4, Thomas Griffin5, Ekaterina Alexeeva6, John Bohnsack7, Andrew Zeft8, Gerd Horneff9, Richard Vehe10, Valda Stanevicha11, Stacey Tarvin12, Maria Trachana13, Adam Huber14, Daniel Kietz15, Ilonka Orban16, Jason Dare17, Ivan Foeldvari18, Pierre Quartier19, Alyssa Dominique20, Tzuyung Douglas Kou20, Robert Wong20, Alberto Martini21, Hermine Brunner3 and Nicolino Ruperto22, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Anna Meyer Children's Hospital, Firenze, Italy, 5Levine Children's Hospital, Charlotte, NC, 6Scientific Center of Children’s Health of RAMS, Moscow, Russia, 7University of Utah and Primary Children's Hospital, Cincinnati, OH, 8Cleveland Clinic, Cleveland, OH, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10University of Minnesota, Minneapolis, MN, 11Riga Stradins University, Riga, Latvia, 12Riley Children’s Health, Indianapolis, IN, 13Aristotle University of Thessaloniki, Thessaloníki, Greece, 14Dalhousie University, Halifax, NS, Canada, 15Children’s Hospital of Pittsburgh, Pittsburgh, PA, 16National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 17University of Arkansas for Medical Sciences, Little Rock, AR, 18Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 19Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 20Bristol-Myers Squibb Company, Princeton, NJ, 21PRINTO, Istituto Giannina Gaslini, Genova, Italy, 22Istituto Giannina Gaslini, Genova, Italy

Meeting: ACR Convergence 2020

Keywords: Biologicals, Juvenile idiopathic arthritis, Pediatric rheumatology, registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Pediatric Rheumatology – Clinical Poster II: JIA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing Phase IV Pediatric Rheumatology Collaborative Study Group and Paediatric Rheumatology International Trial Organization (PRCSG/PRINTO) registry aims to provide monitoring data from a real-world setting regarding longitudinal effectiveness and safety of abatacept in JIA. Here we assess the effectiveness of abatacept in JIA categories in patients who enrolled ≤1 month after starting abatacept treatment.

Methods: Using a standardized protocol and data collection process, clinical sites enroll patients with JIA currently receiving/starting IV/SC abatacept and follow them for up to 10 years. Patients are assessed at baseline and at 3, 6, 9, 12, and 24 months. Disease-related quality of life and physical function were quantified using the Juvenile Arthritis Multidimensional Assessment Report scale.3 Proportions of patients with JIA-ACR 30, 50, 70, and 90 level of responses were determined using validated definitions based on 5/6 JIA core set measures (CRP/ESR not included).4 The clinical 10-joint Juvenile Arthritis Disease Activity Score (cJADAS10) used validated cut-offs for low disease (LD) and inactive disease (ID) activity.5 Disease remission was defined as cJADAS10-validated ID for ≥6 months. As-observed analysis is presented.

Results: As of March 31, 2018, 115 patients were included. Of these, 93 (80.9%) were female, the baseline mean (median) age at enrollment was 12.8 (13.1) years, and disease duration was 60.0 (42.1) months. The JIA categories identified were: polyarticular RF–, 52 (45.2%); oligoarticular, 36 (31.3%); polyarticular RF+, 11 (9.6%); enthesitis-related arthritis (ERA), 9 (7.8%); psoriatic and undifferentiated, 3 (2.6%) each; systemic, 1 (< 1%) (Table 1; patient with systemic JIA excluded). The proportions of patients achieving JIA-ACR responses, cJADAS10 LD, cJADAS10 ID and cJADAS10 remission are shown in Figure 1 (patient with systemic JIA excluded).

Conclusion: Abatacept treatment resulted in rapid, clinically important and sustained JIA-ACR responses in all JIA categories with polyarticular or oligoarticular disease course and few achieved cJADAS10 ID and cJADAS10 remission status. Quality of life was also improved across JIA categories over time, as per JAMAR QoL scores. Limitations of the study include a low number of patients with ERA, psoriatic, undifferentiated, and systemic JIA.

References:

  1. Brunner HI, et al. Arthritis Rheumatol 2018;70:1144–1154.
  2. Ruperto N, et al. Lancet 2008;372:383–391.
  3. Solari N, et al. Pediatr Rheumatol Online J 2008;6(Suppl 1):P106.
  4. Giannini EH, et al. Arthritis Rheum 1997;40:1202–1209.
  5. Consolaro A, et al. Arthritis Care Res (Hoboken) 2014;66:1703–1709.

Medical writing: Katerina Kumpan, PhD (Caudex).


Disclosure: D. Lovell, AstraZeneca, 5, Boehringer Ingelheim, 5, Bristol-Myers Squibb, 2, Forest Research, 5, GlaxoSmithKline, 5, Janssen, 2, Novartis, 2, 5, Roche, 2, 5, UBC, 2, 5, AbbVie, 2, Pfizer Inc, 2, 5, Abbott, 5, Amgen, 5, Celgene, 5, Takeda, 5, Wyeth, 5; N. Tzaribachev, None; E. Morgan, None; G. Simonini, Novartis, 5, 8, AbbVie, 5, 8; T. Griffin, None; E. Alexeeva, Novartis, 2, 5, 8, Roche, 2, 5, 8, Pfizer, 2, 5, 8, AbbVie, 2, 5, 8; J. Bohnsack, AbbVie, 2, Bristol-Myers Squibb, 2, Janssen, 2, Pfizer Inc, 2, Roche, 2; A. Zeft, Merck, 4, Teva, 4, Opko Health, 4; G. Horneff, Pfizer, 5, 8, AbbVie, 5, 8, Novartis, 5, 8, Sanofi, 5, 8; R. Vehe, None; V. Stanevicha, None; S. Tarvin, None; M. Trachana, AbbVie, 2, Bristol Myers Squibb, 2, Novartis Hellas, 2, 8, Pfizer, 8, Roche, 8; A. Huber, None; D. Kietz, None; I. Orban, None; J. Dare, AbbVie, 2, Bristol Myers Squibb, 2, Pfizer, 2, Roche, 2, UCB, 2, Centene Corporation, 3, 4; I. Foeldvari, Novartis, 5, Amgen, 5, Pfizer, 5, Bristol Myers Squibb, 5, Sanofi, 5, Eli Lilly, 5; P. Quartier, AbbVie, 1, Bristol-Myers Squibb, 1, Chugai-Roche, 1, Lilly, 1, Novartis, 1, Novimmune, 1, Sanofi, 1, Sobi, 1; A. Dominique, Bristol-Myers Squibb Company, 1, 3, 4; T. Kou, Bristol-Myers Squibb Company, 1, 3; R. Wong, Bristol-Myers Squibb Company, 1, 3, 4; A. Martini, AbbVie, 8, Eli Lilly, 8, EMD Serono, 8, Janssen, 5, 8, Pfizer Inc, 5, 8, Novartis, 5, 8; H. Brunner, Abbott, 5, Amgen, 5, AstraZeneca, 5, Boehringer Ingelheim, 5, Celgene, 5, GlaxoSmithKline, 5, 8, F Hoffman-La Roche, 5, 8, Novartis, 5, 8, Pfizer, 5, Takeda, 5, UBC, 5, Wyeth, 5; N. Ruperto, Ablynx, 5, 8, Astrazeneca-Medimmune, 5, 8, Biogen, 5, 8, Boehringer, 5, 8, Bristol Myers Squibb, 2, 5, 8, 9, Eli Lilly, 2, 5, 8, 9, EMD Serono, 5, 8, GlaxoSmithKline, 2, 5, 8, 9, F Hoffmann-La Roche, 2, 5, 8, 9, Janssen, 2, 5, 8, 9, Merck, 5, 8, Novartis, 2, 5, 8, 9, Pfizer, 2, 5, 8, 9, R-Pharma, 5, 8, Sanofi, 5, 8, Servier, 5, 8, Sinergie, 5, 8, Sobi, 2, 5, 8, 9, AbbVie, 5, 8, Takeda, 5, 8.

To cite this abstract in AMA style:

Lovell D, Tzaribachev N, Morgan E, Simonini G, Griffin T, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevicha V, Tarvin S, Trachana M, Huber A, Kietz D, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou T, Wong R, Martini A, Brunner H, Ruperto N. Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/response-to-abatacept-in-jia-categories-results-from-the-prcsg-printo-jia-abatacept-phase-iv-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/response-to-abatacept-in-jia-categories-results-from-the-prcsg-printo-jia-abatacept-phase-iv-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology